Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

QIAGEN broadens molecular diagnostic reach with ESE GmbH acquisition
February 2010
SHARING OPTIONS:

VENLO, The Netherlands—QIAGEN N.V. announced in January that its acquisition of ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices based in Stockach, Germany, for $19 million in cash. ESE has pioneered the development and manufacturing of optical measurement systems for medical and industrial applications. The systems utilize unique, high-performance and fluorescence detection technologies integrated into compact modules. According to QIGEN, ESE's solutions are considered an emerging standard for the detection of fluorescent signals in a wide range of molecular testing applications, most notably in nucleic acid-based point-of-need testing. QIAGEN says the acquisition adds a novel detection platform to its portfolio of assay technologies and enables it to offer such solutions for a broad range of molecular diagnostic segments in Europe, Latin America and Asia.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.